Argus downgraded Novo Nordisk (NVO) to Hold from Buy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- LLY, PFE: Eli Lilly’s Mounjaro, Pfizer’s Cancer Drug Added to China’s State Insurance List
- Mixed options sentiment in Novo Nordisk with shares up 0.39%
- Eli Lilly Stock (LLY) Gets Multiple Price Target Increases as Rally Continues
- Eli Lilly price target raised to $1,163 from $1,036 at Guggenheim
- Novo Nordisk price target lowered to $42 from $43 at Morgan Stanley